Bridge Biotherapeutics has completed enrollment for a Phase II trial of BBT-877, an autotoxin inhibitor for idiopathic pulmonary fibrosis. The study aims to evaluate efficacy, safety, and tolerability, with results expected in the first half of next year.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing